Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Equivir G
- Development stage
- Preclinical
- Lead developer
- ProPhase Labs
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
**Equivir G** is an investigational prescription antiviral formulation consisting of the Equivir FDA Generally Recognized as Safe eligible polyphenol blend with added gallic acid. It is being developed as a broad-based antiviral candidate for respiratory viral infections and other viral diseases. Public sponsor materials describe demonstrated antiviral activity, but do not disclose a validated molecular target, specific viral protein target, or clinical efficacy for Equivir G. Global Research and Discovery Group originated the proprietary compounds; Global BioLife and Impact BioMedical have held development rights, while ProPhase Labs obtained worldwide development and commercialization rights and stated that it intended to prepare an FDA Investigational New Drug application for Equivir G. ([impactbiomedinc.com](https://www.impactbiomedinc.com/equivir/))
- Other names
- Equivir GEquivir-G
02
Targets
ACE2 (Angiotensin-converting enzyme 2)ICAM1 (Intercellular Adhesion Molecule 1)NeuraminidaseRdRp (Coronavirus RNA-dependent RNA polymerase)NSP13 (SARS-CoV-2 helicase)Mpro (3C-like proteinase of SARS-CoV-2)
Beyond the preview
Go deeper on Equivir G.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Equivir G.